Companies: 10,795·Total market cap: $144.5T
BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp.

BGLCNASDAQHealthcare● Active
$2.19
$-0.01(-0.45%)
Market Cap$4405448
P/E Ratio
52W High$15.6
52W Low$1.92

BioNexus Gene Lab Corp.(BGLC)· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。

FMP · BGLC · 截至 2026-06-09

财务报表

Revenue · Gross Profit · Net Income
Breakdown2025-122024-122023-122022-122021-12
Revenue
Revenue$7.42M$9.51M$9.77M$10.93M$13.36M
Cost of Revenue$6.34M$8.22M$8.44M$9.67M$11.17M
Gross Profit$1.09M$1.29M$1.33M$1.26M$2.19M
Gross Margin %(computed)14.62%13.56%13.61%11.52%16.42%
Operating Expenses
R&D Expenses$0.05M$0.05M$0.05M$0.00M$0.00M
G&A Expenses$2.33M$1.97M$2.44M$1.73M$1.20M
Total Operating Expenses$4.24M$2.86M$3.92M$1.55M$1.14M
Operating Income($3.16M)($1.57M)($2.59M)($0.29M)$1.06M
Operating Margin %(computed)-42.54%-16.55%-26.54%-2.66%7.90%
Interest Income$0.08M$0.15M$0.00M$0.00M$0.00M
Interest Expense$0.02M$0.02M$0.01M$0.01M$0.01M
Income Before Tax($2.98M)($1.59M)($2.61M)($0.30M)$1.04M
Income Tax Expense$0.00M$0.00M$0.02M$0.05M$0.29M
Net Income($2.98M)($1.60M)($2.63M)($0.36M)$0.75M
Net Margin %(computed)-40.20%-16.81%-26.91%-3.26%5.62%
Per Share & EBITDA
EPS (Basic)$-1.61$-0.90$-1.53$-0.25$0.53
Wtd Avg Shares1.86M1.78M1.72M1.44M1.43M
EBITDA($2.80M)($1.42M)($2.49M)($0.19M)$1.16M
EBITDA Margin %(computed)-37.67%-14.94%-25.43%-1.70%8.71%

数据来源:Financial Modeling Prep · 最后更新:2026-06-09 · USD · M

深入了解BioNexus Gene Lab Corp.

关于BioNexus Gene Lab Corp.(BGLC)损益表

BioNexus Gene Lab Corp.(BGLC)损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年,BGLC实现营收$0.01B,毛利润$0.00B(毛利率14.62%),净利润($0.00B)(净利率-40.20%)。

常见问题

BGLC · 4 问

BioNexus Gene Lab Corp.(BGLC)2025财年营收为$0.01B,同比down21.9%。

BGLC revenueBGLC salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09